Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2006

View Archived Issues

Chugai reviews progress at home and overseas

Financing at Microbia to fund pipeline development

ZIO-201 activity, safety evaluated in preclinical models

Hormone-refractory prostate cancer patients respond to second-line taxane therapy

Enrollment target reached in phase IIIb study of Onconase

New phase II study to evaluate MF-101 for menopausal symptoms

Statistically significant results in Levulan PDT study

rhCD59-P represents a novel approach for PNH therapy

Pfizer's novel SSRI chosen as a clinical candidate

Novel potential antiemetics emerge from Merck Sharp and Dohme

NPS to advance development of teduglutide for Crohn's disease

Epitan changes name to Clinuvel, initiates new program in actinic keratosis

ImQuest licenses pyrimidinedione series of anti-HIV compounds from Samjin

Biotron compounds show activity against avian flu

IDM plans NDA submission for Junovan in osteosarcoma for 2006

Satraplatin MAA targeted for Q1 2007

ARQ-171 begins GLP toxicity studies

OrthoLogic forms alliance with Quintiles for Chrysalin

Memory and Roche amend nicotinic alpha-7 agonist agreement

Memory completes discovery work in PDE4 inhibitor collaboration with Roche

Apidra now available to treat hyperglycemia in diabetes patients

Positive profile reported for rEV-131

Therapeutic agents for gastrointestinal disorders claimed in recent patent literature

Novel agents imparted for the treatment of inflammatory disorders

Therapeutic agents for HIV infection reported in recent Gilead patent

BioCryst Pharmaceuticals presents new data on BCX-3607

Antiviral treatment more effective against monkeypox than vaccination post-exposure

Inhibition of ERK signaling pathway as a therapeutic intervention against drug addiction